Wells Fargo & Co. (NYSE: WFC)�may be Warren Buffett’s favorite bank hands down and it may be the safest of the money center and banking giants now. It turns out that if you work for that bank in the mortgage services unit, it might not be the safest bank when it comes to job security. Reports hit late in the day on Wednesday from Bloomberg, CNBC, and other media outlets�that Wells Fargo was laying off some 2,300 mortgage related jobs. It turns out that the refinancing boom has been crushed by a 100 to 125 basis point rise in mortgages.
The home-lending unit is based in Des Moines, Iowa and the cuts are being spread out around the nation. Frankly, this is not that surprising when you consider what has happened with interest rates. In fact, refinancings were peaking even before mortgage rates hit a low because those who could refinance had already done so.
It turns out that this will make the total layoffs since July come to roughly 3,000. Wells Fargo is the king of mortgage banking, which means it also has the most to lose in opportunity costs. The bank’s total headcount of almost 275,000 workers implies that just over 1% will have been let go. Whether or not more jobs will be terminated if rates keep rising and/or if housing slows is up to you to decide.
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-term drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ilop! eridone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated with human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide development, manufacturing and commercialization rights, and, in ad! dition to! the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion: - [By CRWE]
Today, TTNP surged (+2.76%) up +0.018 at $.689 with 152,996 shares in play thus far (ref. google finance Delayed: 2:02PM EDT October 1, 2013).
Titan Pharmaceuticals, Inc. previously reported that the U.S. Food and Drug Administration (FDA) has granted the request for a meeting to discuss Probuphine庐. The meeting is scheduled for November 19, 2013. The FDA has designated this as a Type C meeting and has requested the submission of briefing materials by October 7, 2013.
Top 10 Safest Companies To Buy Right Now: Respect Your Universe Inc (RYUN)
Respect Your Universe, Inc. (RYU), incorporated on November 21, 2008, in a start-up stage company. The Company focuses on capitalizing mixed martial arts (MMA) and similar fighting styles and design, market and sell sportswear and competition apparel directed toward the worldwide MMA fan base. Its product line focuses on apparel that is designed for MMA training and competition, as well as a broader and more mainstream post-competition sportswear category. In October 2012, the Company announced the opening of their first retail location at The Shoppes at the Palazzo in Las Vegas, Nevada.
The Company�� product is classified into three categories: Training, Competition and Lifestyle. Its training apparel includes compression tops and compression shorts, training shorts, training hoodies, t-shirts and duffel bags. Competition wear includes MMA competition shorts. Sportswear includes t-shirts, hoodies, beanies and shorts. In the lifestyle classifications the Company has created products, which include Organic Graphic Tee shirts, in tank, Short sleeve, and long sleeve; Organic Hoody�� full zip and pullover made from premium heavyweight organic cotton fleece, and Bamboo Rayon Tee��.
Advisors' Opinion: - [By Peter Graham]
Small cap stocks Respect Your Universe Inc (OTCMKTS: RYUN), Global Gaming Network (OTCMKTS: GBGM) and Innocap, Inc (OTCBB: INNO) have been getting some attention lately in various investment newsletters thanks in part to paid promotions or investor relations activities. Of course there is nothing wrong with properly disclosed paid promotions or investor relations type of activities, but they can come back and bite unwary traders or investors. So what should you do with these three small cap stocks? Here is a quick reality check:
Top 10 Safest Companies To Buy Right Now: Integrated Electrical Services Inc.(IESC)
Integrated Electrical Services, Inc. provides electrical infrastructure services in the United States. The company?s Communications segment offers various services, including the design, installation, and maintenance of network infrastructure for the financial, medical, hospitality, government, manufacturing, educational, and information technology industries; design and installation of audio/visual, telephone, fire, wireless, and intrusion alarm systems, as well as design/build, servicing, and maintenance of data network systems. Its Residential segment offers electrical installation services for single-family housing and multi-family apartment complexes, and CATV cabling installations for residential and commercial applications. This segment also installs residential solar power, smart meters, electric car charging stations, and stand-by generators. The company?s Commercial and Industrial segment provides electrical contracting services, which include the design of ele ctrical systems in a building or complex; procurement and installation of wiring and connection to power sources; end-use equipment and fixtures; and contract maintenance services. It also provides service, maintenance, and renovation and upgrade work services; and services for various projects, including high-rise residential and office buildings, power plants, manufacturing facilities, data centers, chemical plants, refineries, wind farms, solar facilities, municipal infrastructure, and health care facilities, as well as residential developments. In addition, this segment offers utility services consisting of overhead and underground installation and maintenance of electrical and other utilities transmission and distribution networks; installation and splicing of high-voltage transmission and distribution lines; substation construction; and substation and right-of-way maintenance. Integrated Electrical Services, Inc. was founded in 1997 and is based in Houston, Texas.
Advisors' Opinion: - [By GuruFocus]
Integrated Electrical Services Inc. (IESC): President and CEO James M. Lindstrom Bought 1,901 Shares
President and CEO of Integrated Electrical Services Inc. (IESC) James M. Lindstrom bought 1,901 shares on 09/25/2013 at an average price of $4.08. Integrated Electrical Services Inc. has a market cap of $73.0559 million; its shares were traded at around $4.08 with and P/S ratio of 0.13.
Top 10 Safest Companies To Buy Right Now: Conatus Pharmaceuticals Inc (CNAT)
Conatus Pharmaceuticals Inc., incorporated on July 13, 2005, is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The Company has designed a clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease. The Company�� initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure (ACLF), chronic liver failure (CLF), and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT).
The Company has completed two placebo-controlled Phase II trials in patients with liver disease showing reductions in ALT levels that occur rapidly, within as little as one day after initiation of therapy, and are maintained throughout the treatment period. In the Company�� 204-patient Phase 2b trial, it also measured cCK18, an important biomarker of apoptosis and disease severity. Emricasan has been generally well-tolerated in all of the clinical studies. As of July 23, 2013, the Company had not generated any revenue.
Advisors' Opinion: - [By John Udovich]
While Intercept Pharmaceuticals Inc (NASDAQ: ICPT) surged earlier this year and Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) has surged this week after Merck & Co. Inc (NYSE: MRK) agreed to purchase hepatitis stock�Idenix Pharmaceuticals Inc (NASDAQ: IDIX) at a 239% premium, it seems the herd has realized that small cap Conatus Pharmaceuticals Inc (NASDAQ: CNAT) is also a liver disease stock as shares suddenly surged 56.69% on no apparent company news. But just what is�Conatus Pharmaceuticals and is it worth taking a chance on?
- [By Lauren Pollock]
Conatus Pharmaceuticals Inc.'s(CNAT) shares jumped 26% to $7.75 premarket after the biotechnology firm said its treatment for chronic liver disease has been granted a status that could mean quicker approval.
Top 10 Safest Companies To Buy Right Now: Everest Re Group Ltd.(RE)
Everest Re Group, Ltd., together with its subsidiaries, underwrites reinsurance and insurance in the United States (the U.S.), Bermuda, and international markets. The company operates in five segments: U.S. Reinsurance, U.S. Insurance, Specialty Underwriting, International, and Bermuda. The U.S. Reinsurance segment writes property and casualty reinsurance, on both a treaty and facultative basis, through reinsurance brokers, as well as directly with ceding companies within the United States. The U.S. Insurance segment offers property and casualty insurance primarily through general agents, brokers, and surplus lines brokers in the U.S. The Specialty Underwriting segment writes accident and health, marine, aviation, and surety business within the U.S. and worldwide through brokers and directly with ceding companies. The International segment offers non-U.S. property and casualty reinsurance. The Bermuda segment provides reinsurance and insurance to worldwide property and cas ualty markets and reinsurance to life insurers through brokers and directly with ceding companies, as well as offers reinsurance to the United Kingdom and European markets. The company was founded in 1973 and is based in Liberty Corner, New Jersey.
Advisors' Opinion: - [By John Emerson]
Last August, I purchased Everest Re (RE) when it fell within the value parameters outlined in today's article. I wrote an article about the stock titled: Everest Re: Low Risk High Reward http://www.gurufocus.com/news/143388/everest-re-low-risk-high-reward
- [By Marc Bastow]
Reinsurance and insurance underwriters Everest Re Group (RE) raised its dividend 56% to 75 cents per share, payable on Dec. 18 to shareholders of record as of Dec. 4.
RE Dividend Yield: 1.92%
Top 10 Safest Companies To Buy Right Now: Healthways Inc.(HWAY)
Healthways, Inc., through its subsidiaries, provides specialized, comprehensive solutions to assist people to maintain and enhance their health and well-being. The company?s evidence-based programs provide specific and personalized interventions for each individual in a population, irrespective of age, or health status; and delivers to consumers by phone, mail, Internet, and face-to-face interactions. It also offers wellness and disease prevention solutions through total population screening, well-being assessments, and supportive interventions; access to health improvement programs, such as fitness solutions, weight management, chiropractic, and complementary and alternative medicine; and educational materials and personal interactions with trained nurses and other healthcare professionals to create and sustain healthier behaviors for individuals who are in the early stages of chronic conditions. In addition, the company operates care enhancement and coaching centers; fi tness centers; and provides health improvement programs and services in Brazil, Australia, and France. Healthways, Inc. delivers its programs to various customers, including health plans, employers, integrated healthcare systems, hospitals, physicians, and government entities in the United States, the District of Columbia, and Puerto Rico. The company was founded in 1981 and is headquartered in Franklin, Tennessee.
Advisors' Opinion: - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Healthways (Nasdaq: HWAY ) , whose recent revenue and earnings are plotted below.
- [By Lauren Pollock]
Healthways Inc.'s(HWAY) profit fell 64%, hurt by shrinking margins and flat revenue. Shares of Healthways fell as the company lowered its guidance for the year, while issuing downbeat estimates for the fourth quarter and 2014.
- [By Holly LaFon]
The last company I want to mention is HealthWays (HWAY), which was once a small-cap growth stock favorite. Due to increasing changes in the U.S. healthcare industry, as well as confusion around the implementation of ObamaCare, the company recently expanded its business to not just physical wellness but to social and emotional wellness, health, and nutrition.
Top 10 Safest Companies To Buy Right Now: Cameco Corporation(CCJ)
Cameco Corporation operates as a uranium producer, supplier of conversion services, and fuel manufacturer. The company?s Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. Its operating uranium properties include the McArthur River and Key Lake, and Rabbit Lake located in Saskatchewan, Canada; the Crow Butte located in Nebraska and the Smith Ranch-Highland located in Wyoming; and the Inkai uranium deposit located in Kazakhstan. Cameco Corporation?s Fuel Services segment engages in the refining, conversion, and fabrication of uranium concentrate; and the purchase and sale of conversion services. Its products include uranium trioxide, uranium hexafluoride, and uranium dioxide. This segment also manufactures fuel bundles, reactor components, and monitoring equipment to Candu reactors; and provides nuclear fuel and consulting services to Candu operators. The company?s Electricity segment engages in the generation and sale of nuclear electricity, through its 31.6% interest in Bruce Power L.P. This segment operates four nuclear reactors at the Bruce B generating station in southern Ontario, Canada. The company was founded in 1987 and is headquartered in Saskatoon, Canada.
Advisors' Opinion: - [By Jim Wallingford]
Cameco (CCJ) was created in 1988 through the merger of two Canadian crown (government-owned) corporations. It's IPO debuted on the Toronto exchange in 1991 and a NYSE listing occurred in 1996. The McArthur River mine, the highest grade mine in the world (16.36% U3O8, 100 times the global average), began production in November 2000. Cameco's share of the proven and probable resources is 264 mil lbs. The mine has produced 230 mil lbs in the last 13 years. CCJ's current year share is over 13 mil lbs.
- [By Selena Maranjian]
Among holdings in which GMT Capital increased its stake was Canada-based uranium specialist Cameco (NYSE: CCJ ) . The company's business is expected to improve as gas and coal prices eventually rise, and also due to new nuclear plants being built. My colleague Sean Williams likes Cameco's transparency, expects higher uranium prices, and notes that China is also expected to demand more uranium over time. Some see the stock having a fair chance to appreciate substantially.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, uranium producer Cameco (NYSE: CCJ ) has earned a respected four-star ranking.
- [By Joshua Bondy]
Cameco (NYSE: CCJ ) is the world's preeminent pure-play uranium miner. It has a host of high-quality mines and a small total debt-to-equity ratio of 0.25. Its margins are low as the industry is still recovering from Fukushima, but this has allowed Cameco to buy up assets from potentially dangerous competitors. The good news is that its gross margin of 35.2% lets it sit back and watch the market recover.